We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App





New Rapid Test That Identifies Deteriorating COVID-19 Patients with Greater Accuracy than Existing Tests Presented at AACC 2021

By LabMedica International staff writers
Posted on 28 Sep 2021
Print article
Illustration
Illustration

A groundbreaking study on a new rapid test that identifies COVID-19 patients who will deteriorate with greater accuracy than existing tests was presented at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo.

A team of researchers from MeMed (Haifa, Israel) has developed the test that predicts COVID-19 outcomes with high accuracy. In 15 minutes, the test measures blood levels of TRAIL and IP-10, two proteins that the immune system produces in response to viral infections, and CRP, a general marker of infection severity. The test then uses these values to calculate a COVID-19 Severity score on a scale of 0-100, with 100 indicating the highest likelihood of severe outcome.

To develop this test, the researchers first used a rapid point-of-care instrument that MeMed previously built to measure TRAIL, IP-10, and CRP in a group of 518 COVID-19 patients, 113 of whom had a severe outcome. The researchers analyzed the data from this group with a machine learning algorithm in order to create the model that serves as the basis for the COVID-19 Severity score. Through statistical analysis, the researchers then determined that the COVID-19 Severity score has an area under the curve (AUC) of 0.86. This means that it outperforms other COVID-19 severity stratification tests in terms of accuracy, including the commonly used biomarker IL-6, which only has an AUC of 0.77.

“There are three elements that are novel about this test,” said Eran Eden, PhD, Co-founder & CEO of MeMed. “First, we’re using the body’s immune response to tell us what’s going on with the patient. Second, instead of using just one biomarker, we’re combining three complementary markers to get a more holistic picture. And third, we’re using a novel platform that is able to measure these specific proteins from blood within 15 minutes, making this test clinically applicable to the workflow in today’s emergency departments.”

Related Links:
MeMed

New
Gold Member
Syphilis Screening Test
VDRL Antigen MR
Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
New
Urine Drug Test
Instant-view Buprenorphine Urine Drug Test
New
STI Test
cobas TV/MG

Print article
ADLM

Channels

Microbiology

view channel
Image: The breakthrough system offers a faster way to diagnose bloodborne infections (Photo courtesy of Melio)

Culture-Free Platform Rapidly Identifies Blood Stream Infections

Neonatal sepsis is a life-threatening condition that results from bloodstream infections in newborns under 28 days old. Due to their immature immune systems, newborns are especially vulnerable to infections.... Read more

Pathology

view channel
Image: The technique predicts how well some breast cancer patients will respond to chemotherapy (Photo courtesy of Shutterstock)

New Technique Predicts Tumor’s Responsiveness to Breast Cancer Treatment

Breast cancer is the most common cancer among women worldwide, with 2.3 million new cases diagnosed each year. In the era of personalized medicine, targeted therapies for different types of breast cancer... Read more

Technology

view channel
Image: Human tear film protein sampling methods (Photo courtesy of Clinical Proteomics. 2024 Mar 13;21:23. doi: 10.1186/s12014-024-09475-8)

New Lens Method Analyzes Tears for Early Disease Detection

Bodily fluids, including tears and saliva, carry proteins that are released from different parts of the body. The presence of specific proteins in these biofluids can be a sign of health issues.... Read more

Industry

view channel
Image: The game-changing immunoassay diagnostics platform delivers results from whole blood sample in 10 minutes (Photo courtesy of SpinChip)

bioMérieux Acquires Norwegian Immunoassay Start-Up SpinChip Diagnostics

bioMérieux (Marcy l’Étoile, France) has agreed to acquire SpinChip Diagnostics (Oslo, Norway), the developer of a game-changing immunoassay diagnostics platform. The small benchtop analyzer is well adapted... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.